Laws and Labels: A Regulatory View of Biosimilars
Now that the first biosimilar product has been approved by FDA, healthcare professionals need to get up to speed on the evolving rules and policies that will separate biosimilars from interchangeable biologics and branded products. Join healthcare legal expert Erika Lietzan for a webinar examining the latest from the FDA on labeling biosimilars, the scientific and legal differences between biosimilars and other products, and the potential impact on prescribing and dispensing practices.
You may also like:
It may not be exciting or cutting-edge, but the pharmaceutical supply chain and pharmacy profession’s operations are tied to an infrastructure that depends on a 10- or 11-digit number: the
A recent study found the use of non-steroidal anti-inflammatory drugs (NSAIDs) in combination with oral anticoagulant therapy in patients with atrial fibrillation was associated with an increased risk of major bleeding compared...
Last week, the U.S. Senate passed its ambitious Opioid Crisis Response Act of 2018 (S.2680) by a vote of 99 to 1. The bill differs...
Stay in the Know
Sign up to start receiving notifications via email of our upcoming webinars!